ArticleBreast cancer research and treatment2026
Unlocking the predictive value of post-neoadjuvant immune biomarkers in breast cancer: neutrophil-to-lymphocyte ratio (NLR) and systemic immune-inflammation index (SII).
Article in Breast cancer research and treatment, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Prognostic value of pretreatment neutrophil-to-lymphocyte ratio in breast cancer patients receiving neoadjuvant chemotherapy: a systematic review and meta-analysis.Frontiers in oncology · 2026Pooled it
- Predictive Value of the Inflammatory Burden Index for Pathological Complete Response in HER2-Positive and Triple-Negative Breast Cancer Receiving Neoadjuvant Chemotherapy: A Comparative Analysis with Conventional Inflammatory Indices.Journal of clinical medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo evaluate the potential prognostic value of two peripheral immune biomarkers-neutrophil-to-lymphocyte ratio (NLR) and systemic immune-inflammation index (SII)-in breast cancer patients treated with neoadjuvant chemotherapy, and to assess their association with pathological complete response (pCR) and other predictive factors. In addition, to determine whether prognostic or predictive differences exist between baseline and post-neoadjuvant values of these biomarkers.
methodsWe analyzed 801 women with early breast cancer treated with neoadjuvant chemotherapy, evaluating clinical and pathological data, survival outcomes, NLR (continuous and categorical) and SII.
resultsBaseline NLR was significantly higher in younger patients, in those with positive pathological nodes, and in the HER2 + /HR - subtype, while baseline SII was elevated in the triple-negative subtype. Post-neoadjuvant chemotherapy (post-NCT) NLR and SII showed only weak associations with estrogen receptor expression, yet both were independently associated with pCR (post-NCT NLR: OR = 0.91; 95% CI: 0.84-0.98; p = 0.02; post-NCT SII: OR = 0.65; 95% CI: 0.47-0.89; p = 0.008). Neither biomarker showed a significant impact on overall or progression-free survival.
conclusionPost-treatment NLR and SII may reflect chemotherapy-induced immune changes and are associated with pathological complete response, but their additional predictive value is uncertain, and no prognostic impact was observed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.